4sc-203
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2010 (NCT01054937)
Timeline
2010s
- Jan 1, 2010
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
FLT3 inhibitor
Vascular endothelial growth factor receptor inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1ccc(C)cc1NC(=O)Nc1nc2ccc(Nc3ncnc4cc(OCCCN5CCN(C)CC5)c(OC)cc34)cc2s1- Mol. weight
- 642.79 g/mol
- Lipinski Ro5
- 3 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314406 ↗
- ChEMBLCHEMBL3545358 ↗
Also known as
- 4sc-203
- 4sc-203
- 4sc-203
- 4sc-203
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01054937 | Phase 1 | Jan 1, 2010 | 4SC AG |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 4SC AG | For profit | 1 | 1 | 1 | 2010 |
1 organizations
Page 1 / 1